Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients

Abstract.  Ringdén O, Labopin M, Beelen DW, Volin L, Ehninger G, Finke J, Greinix HT, Kyrcz‐Krzemien S, Bunjes D, Brinch L, Niederwieser D, Arnold R, Mohty M, Rocha V, for the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (Karolinska University Hospital Huddinge, Sweden; CEREST‐TC EBMT, Paris, France; University of Duisburg‐Essen, Germany; Helsinki University Central Hospital, Helsinki, Finland; University Hospital, Dresden, Germany; University Hospital, Freiburg, Germany; Medical University Vienna, Vienna, Austria; Medical University of Silesia, Katowice, Poland; University Hospital, Ulm, Germany; Rikshospitalet, Oslo, Norway; University Hospital, Leipzig, Germany; Charité University Hospital, Berlin, Germany; Université de Nantes, Nantes, France; and Hôpital Saint‐Louis, Paris, France). Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. J Intern Med 2012; 272: 472–483.

[1]  A. Gratwohl,et al.  The EBMT activity survey 2009: trends over the past 5 years , 2011, Bone Marrow Transplantation.

[2]  K. Matsuo,et al.  Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry , 2010, International journal of hematology.

[3]  N. Schmitz,et al.  Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. , 2010, The Lancet. Oncology.

[4]  A. Barrett,et al.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. , 2009, Blood.

[5]  A. Gratwohl,et al.  The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products , 2008, Bone Marrow Transplantation.

[6]  J. Wagner,et al.  Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  M. Remberger,et al.  Similar Outcome After Unrelated Allogeneic Peripheral Blood Stem Cell Transplantation Compared With Bone Marrow in Children and Adolescents , 2007, Transplantation.

[8]  R. Hills,et al.  Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Remberger,et al.  Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. , 2005, Blood.

[10]  J. Klein,et al.  Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Bourhis,et al.  Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.

[12]  R. Gale,et al.  Decreased treatment failure in recipients of HLA‐identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses , 2003, British journal of haematology.

[13]  M. Labopin,et al.  Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow , 2003, Bone Marrow Transplantation.

[14]  M. Labopin,et al.  Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Bourhis,et al.  Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. , 2002, Blood.

[16]  M. Remberger,et al.  No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. , 2001, Blood.

[17]  D. Paniagua,et al.  Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Hillyer.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives In patients with hematologic cancers , 2001 .

[19]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[20]  A. Fauser,et al.  Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study , 2001, Bone Marrow Transplantation.

[21]  N. Schmitz,et al.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). , 2000, Blood.

[22]  G. Tjønnfjord,et al.  A randomised study of allogeneic transplantation with stem cells from blood or bone marrow , 2000, Bone Marrow Transplantation.

[23]  J. Bourhis,et al.  Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Remberger,et al.  Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. , 1999, Blood.

[25]  J P Klein,et al.  Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.

[26]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[27]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[28]  F. Aranha,et al.  A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies , 1998, Bone Marrow Transplantation.

[29]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[30]  K. Sullivan,et al.  Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. , 1997, Blood.

[31]  R. Storb,et al.  Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. , 1995, Blood.

[32]  N. Schmitz,et al.  Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease. , 1995, Bone marrow transplantation.

[33]  N. Schmitz,et al.  Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.

[34]  P. Hougaard,et al.  Frailty models for survival data , 1995, Lifetime data analysis.

[35]  Giralt,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. , 1995, Blood.

[36]  N. Schmitz,et al.  Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation [letter] , 1993 .

[37]  N. Schmitz,et al.  Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. , 1993, Blood.

[38]  T. Paulin.  Importance of bone marrow cell dose in bone marrow transplantation. , 1992, Clinical transplantation.

[39]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[40]  A. Rimm,et al.  Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality. , 1983, JAMA.

[41]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[42]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.